The Furoscix ReadyFlow Autoinjector: What a 10-Second Dose Changes

Craig Beavers discusses the higher-concentration subcutaneous furosemide injection in development, which compresses the 5-hour Furoscix infusion into a 5- to 10-second autoinjector administration, functioning much like a traditional IV bolus. Early data, he says, shows it performs very similarly to IV furosemide—the same look and feel, delivered subcutaneously at home. He frames the practical impact: patients no longer wear a device for 5 hours with the associated restrictions, giving them more freedom, while clinicians gain better insight into how quickly a patient responds and whether more aggressive intervention is warranted. On counseling, Beavers notes investigators are exploring bioequivalence to IV furosemide across injection sites—thigh, abdomen, or upper arm—and stresses that proper administration technique is essential for effective delivery. He positions this as no different from counseling on other injectables now common in practice, with pharmacists and nursing staff both key. He addresses injection-site reactions, advising clinicians to ask when irritation occurs, review technique and site cleaning, rotate sites to allow healing, and treat as appropriate. Ahead of the July 26 PDUFA date, he anticipates the formulation could prevent admissions, improve quality of life, and support shared decision-making.